Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?
Cutan Ocul Toxicol
; 42(4): 190-197, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-37452558
ABSTRACT
BACKGROUND:
sh-oligopeptide-1 is a cosmetic that is considered to be the bioequivalent of the Epidermal Growth Factor (EGF).OBJECTIVE:
The systematic search and selection of the information available on sh-oligopeptide-1, and field research on laboratories manufacturing cosmetics and the legal regulation of their products.METHODS:
Specialised search in Medline and Google Scholar (March 2023). A total of 22 references were obtained and 12 articles were selected for analysis, 7 of which were included in Medline. 9 articles correspond to clinical trials that use sh-oligopeptide-1 as equivalent to a functional recombinant human EGF (hr-EGF). The manufacturers are investigated and they are requested to provide scientific information.RESULTS:
Using an inactive ingredient, clinical trials are published with favourable results in order to treat diabetics and cancer patients. These trials do not follow medical standards. Active EGF is not a cosmetic, rather it is a potent unauthorised drug. Likewise, sh-oligopeptide-1 is not a functional EGF, and it is not authorised for medical treatments. Topical hr-EGF is not authorised as a medication in any concentration, except for clinical trials. However, sh-EGF (sh-oligopeptide-1) is authorised as a cosmetic in several different concentrations for generalised use, with unknown long-term risks.CONCLUSION:
Clinical studies on sh-oligopeptide-1 have no scientific basis, as the preclinical bioactivity of this molecule has not been proven.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Cosméticos
/
Factor de Crecimiento Epidérmico
Tipo de estudio:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Cutan Ocul Toxicol
Asunto de la revista:
DERMATOLOGIA
/
OFTALMOLOGIA
/
TOXICOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
España